Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge
This article was originally published in The Pink Sheet Daily
Executive Summary
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.